Yerolatsite Melina, Torounidou Nanteznta, Gogadis Aristeidis, Kapoulitsa Fani, Ntellas Panagiotis, Lampri Evangeli, Tolia Maria, Batistatou Anna, Katsanos Konstantinos, Mauri Davide
Department of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), 45445 Ioannina, Greece.
Cancers (Basel). 2023 Dec 30;16(1):196. doi: 10.3390/cancers16010196.
Gastric cancer (GC) is one of the most common and aggressive types of cancer. Immune checkpoint inhibitors (ICIs) have proven effective in treating various types of cancer. The use of ICIs in GC patients is currently an area of ongoing research. The tumor microenvironment (TME) also seems to play a crucial role in cancer progression. Tumor-associated macrophages (TAMs) are the most abundant population in the TME. TAMs are capable of displaying programmed cell death protein 1 (PD-1) on their surface and can form a ligand with programmed death ligand 1 (PD-L1), which is found on the surface of cancer cells. Therefore, it is expected that TAMs may significantly influence the immune response related to immune checkpoint inhibitors (ICIs).
Understanding the role of TAMs and PD-1/PD-L1 networking in GC.
A systematic review of published data was performed using MEDLINE (PubMed), Embase, and Cochrane databases. We retrieved articles investigating the co-existence of TAMs and PD-1 in GC and the prognosis of patients expressing high levels of PD-1+ TAMs.
Ten articles with a total of 2277 patients were included in the systematic review. The examined data suggest that the expression of PD-L1 has a positive correlation with the infiltration of TAMs and that patients who express high levels of PD-1+ TAMs may have a worse prognosis than those who express low levels of PD-1+ TAMs.
TAMs play a pivotal role in the regulation of PD-1/PD-L1 networking and the progression of GC cells. Nevertheless, additional studies are needed to better define the role of TAMs and PD-1/PD-L1 networking in GC.
胃癌（GC）是最常见且侵袭性最强的癌症类型之一。免疫检查点抑制剂（ICIs）已被证明在治疗多种类型癌症方面有效。目前，ICIs在GC患者中的应用是一个正在进行研究的领域。肿瘤微环境（TME）似乎在癌症进展中也起着关键作用。肿瘤相关巨噬细胞（TAMs）是TME中数量最多的细胞群体。TAMs能够在其表面展示程序性细胞死亡蛋白1（PD-1），并能与癌细胞表面发现的程序性死亡配体1（PD-L1）形成配体。因此，预计TAMs可能会显著影响与免疫检查点抑制剂（ICIs）相关的免疫反应。
了解TAMs和PD-1/PD-L1网络在GC中的作用。
使用MEDLINE（PubMed）、Embase和Cochrane数据库对已发表的数据进行系统综述。我们检索了研究GC中TAMs和PD-1共存以及表达高水平PD-1+ TAMs患者预后的文章。
系统综述纳入了10篇文章，共2277例患者。所检查的数据表明，PD-L1的表达与TAMs的浸润呈正相关，并且表达高水平PD-1+ TAMs的患者可能比表达低水平PD-1+ TAMs的患者预后更差。
TAMs在PD-1/PD-L1网络调节和GC细胞进展中起关键作用。然而，需要更多研究来更好地确定TAMs和PD-1/PD-L1网络在GC中的作用。
Zotero 插件